8-K: Lunai Bioworks Announces 1-for-8 Reverse Stock Split

Lunai Bioworks, Inc. is implementing a 1-for-8 reverse stock split to increase its share price and comply with Nasdaq listing requirements.

Summary

• Lunai Bioworks, Inc. announced a 1-for-8 reverse stock split of its common stock.
• The split is intended to increase the market price per share to meet Nasdaq's minimum bid price requirement of $1.00 for continued listing.
• The reverse stock split is expected to be effective on May 22, 2026, with trading on a split-adjusted basis commencing the same day.
• Following the split, the number of outstanding shares will decrease from approximately 36,271,119 to about 4,533,890.
• Fractional shares will be rounded up to the next whole share.
• This is the second reverse stock split for the company, with a previous 1-for-10 split occurring on September 30, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, as reverse stock splits are often a sign of underlying financial or market price challenges, though it is a necessary step to maintain exchange listing.

Positives

• Aims to regain compliance with Nasdaq's minimum bid price rule ($1.00), potentially preventing delisting.
• The reverse stock split is approved by stockholders and the Board of Directors.
• Fractional shares will be rounded up, which is generally favorable to smaller shareholders.

Negatives

• The reverse stock split does not guarantee a sustained increase in market price.
• May result in reduced liquidity, wider bid-ask spreads, and increased volatility.
• The company previously underwent a 1-for-10 reverse stock split in September 2025, indicating ongoing challenges with share price.

Risks

• The reverse stock split may not result in a sustained increase in the market price of the common stock.
• The split may lead to reduced liquidity, wider bid-ask spreads, or increased volatility.
• The split may not enable the company to regain or maintain compliance with Nasdaq Listing Rule 5550(a)(2) or other continued listing requirements.
• Potential processing delays from Nasdaq, FINRA, or DTC.
• General market conditions, trading prices, and investor acceptance could negatively impact the stock price.
• The effectiveness of the split is subject to Nasdaq Hearings Panel determinations.

Future Outlook

The company expects the reverse stock split to increase its share price to comply with Nasdaq listing rules. However, there are risks that the split may not achieve this goal or could lead to reduced liquidity and increased volatility. The company's ability to maintain Nasdaq compliance remains a key concern.

Management Comments

• The Board of Directors subsequently approved the final 1-for-8 Reverse Stock Split ratio.
• The Reverse Stock Split is intended primarily to increase the market price per share of the Companys Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies struggling to maintain minimum bid price requirements on major exchanges like Nasdaq. This move by Lunai Bioworks is a common strategy in the biotechnology sector, which can be capital-intensive and subject to volatile stock performance, to avoid delisting and potentially attract institutional investors.

Stakeholder Impact

• Shareholders will see their number of shares decrease by a factor of 8, but the total value of their holdings is expected to remain the same immediately after the split, subject to market reaction.
• Beneficial owners holding shares through a bank, broker, or other nominee will have their positions adjusted according to their nominee's procedures.
• The reverse stock split aims to improve the company's ability to meet Nasdaq listing requirements, which is beneficial for maintaining investor confidence and access to public markets.

Next Steps

• The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 22, 2026.
• The company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026.
• The company's common stock will trade under a new CUSIP number, 29350E302, following the effectiveness of the reverse stock split.

Key Dates

Recommendation

The reverse stock split is a procedural move to maintain Nasdaq listing and does not fundamentally alter the company's business prospects. While it addresses a critical compliance issue, it does not inherently improve the company's long-term value or growth trajectory. Investors should hold and await further operational or clinical developments.

Keywords

reverse stock split, Lunai Bioworks, LNAI, Nasdaq compliance, biotechnology, drug discovery, AI, life sciences